Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of azelastine 0.15% nasal spray administered once daily in patients with allergy to Texas mountain cedar pollen.

Author: AmarNiran J, HowlandWilliam C, SacksHarry, WheelerWilliam

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the efficacy of azelastine 0.15% nasal spray administered once daily for treating symptoms of seasonal allergic rhinitis (SAR).
Paper Details　
Original Abstract of the Article :
A previous study with azelastine nasal spray in patients with seasonal allergic rhinitis (SAR) demonstrated that increasing the azelastine concentration from 0.1% to 0.15% allowed for once-daily dosing without increasing the incidence of adverse effects. This study evaluated the efficacy of azelasti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/alr.20065

データ提供：米国国立医学図書館（NLM）

The Quest for Once-Daily Allergy Relief

Allergy research is a constant journey through the desert of sniffles and sneezes. This study dives deep into the world of seasonal allergic rhinitis (SAR), a condition that can make life feel like a sandstorm for many. The researchers were interested in finding a solution that's both effective and convenient for patients. They explored the potential of azelastine nasal spray, a medication commonly used to combat allergies, and investigated whether a higher concentration could make it possible to take it just once a day. They found that increasing the azelastine concentration from 0.1% to 0.15% allowed for once-daily dosing without causing any more side effects.

A Breakthrough for Convenience

This study indicates that using azelastine 0.15% nasal spray once a day can effectively alleviate the symptoms of SAR. Imagine this: no more juggling multiple doses throughout the day, just one quick spritz and you're good to go! This finding could potentially improve the quality of life for many people with SAR.

A Breath of Fresh Air for Allergy Sufferers

This research suggests that a single daily dose of azelastine 0.15% nasal spray might be a game-changer for allergy sufferers. It could mean fewer interruptions to daily life, more freedom to enjoy the outdoors, and perhaps even a little less sniffling and sneezing. Always remember to consult your doctor before making any changes to your allergy treatment plan.

Dr. Camel's Conclusion

This research sheds light on a promising new approach to treating SAR, offering the potential for simpler and more convenient allergy management. It's like finding a cool oasis in the middle of a scorching allergy season! The next step is to see how this finding translates to real-world use. It could be a real game-changer for allergy sufferers who want to enjoy life to the fullest without constantly worrying about their allergies.

Date :
  1. Date Completed 2012-05-18
  2. Date Revised 2016-05-11
Further Info :

Pubmed ID

22287431

DOI: Digital Object Identifier

10.1002/alr.20065

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.